IHS Chemical Week

Markets :: Fine Chemicals/Biotech :: Industrial Biotech

Lonza to Acquire Stake in German Biotech Firm

1:46 AM MDT | October 22, 2009 | Deepti Ramesh

Lonza says it has signed an investment agreement, including a right of first refusal for the commercial production of products, with innovative biotechnology company Cilian (Münster, Germany).  Cilian uses the abilities of ciliates, eukaryotic single-cell micro-organisms, specifically the strain tetrahymena thermophila, for the production of therapeutic proteins and nutritional ingredients. Lonza owns a number of patents and patent applications in the field of tetrahymena thermophila and will transfer these patents and patent applications to Cilian. In...

This information is only available to Chemical Week subscribers.


Forgot your user ID or password?
Click here to have it sent to you.

Risk Free Trial

Email Address

First Name

Last Name

Click here to register and get your RISK-FREE access to chemweek.com

Not an IHS Chemical Week
24/7 member yet?

Here's why you should be:

  • Searchable online archive access of the last 2 years of Chemical Week.
  • Print or digital magazine subscription
  • Price and market change alerts
  • Economic data and statistics
  • Buyers' Guides
  • Webcasts | whitepapers




contact us | about us | customer care | privacy policy | sitemap | advertise

ihsCopyright © 2015 IHS, Inc. All rights reserved. Reproduction in whole or in part without permission is prohibited.

North Asia Russia Southeast Asia China India/Pakistan Middle East Eastern Europe Western Europe Central America Canada USA Australia/New Zealand South America Africa